Meeting Report
Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer
Presented by Heather Wakelee,(1) MD, and Elizabeth S. Waxman,(2) RN, MSN, AOCN®, ANP-BC
1) Stanford University, Stanford Cancer Institute, Stanford, California; 2) The University of Texas MD Anderson Cancer Center, Houston, Texas
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2018;9(3):303–310 |
https://doi.org/10.6004/jadpro.2018.9.3.6 |
© 2018 Harborside™
ABSTRACT
Mutation-targeted therapies have had a major impact on the treatment of NSCLC, even for patients with advanced disease. Methods for detecting mutations, key clinical trials of targeted therapy, and the most common toxicities of EGFR and ALK inhibition were discussed at JADPRO Live.
For access to the full length article, please
sign in.
